Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 25;75(1):29.
doi: 10.1007/s12031-025-02324-9.

Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer's Disease: A Focus on Molecular Mechanisms

Dhyauldeen Aftan AlHayani  1 , Aziz Kubaev  2 , Subasini Uthirapathy  3 , Viralkumar Mandaliya  4 , Suhas Ballal  5 , Rishiv Kalia  6 , Renu Arya  7 , Baneen C Gabble  8   9   10 , Mohammed Qasim Alasheqi  11 , Abed J Kadhim  12
Affiliations
Review

Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer's Disease: A Focus on Molecular Mechanisms

Dhyauldeen Aftan AlHayani et al. J Mol Neurosci. .

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, significantly impacting patients' quality of life. Recent studies have highlighted the roles of sirtuin 1 (SIRT1), a NAD + -dependent deacetylase, in regulating various biological pathways associated with AD pathology, including amyloid-beta metabolism, tau hyperphosphorylation, and neuroinflammation. This review focuses on the therapeutic potential of synthetic and natural compounds that modulate SIRT1 levels, emphasizing their molecular mechanisms of action. We explore a range of SIRT1-modifying agents, including polyphenols such as resveratrol, as well as synthetic analogs and novel pharmaceuticals that aim to enhance SIRT1 activity. Additionally, we discuss emerging innovative therapies, including pharmacological agents that improve SIRT1 signaling through mechanisms like photobiomodulation and nutritional interventions. These compounds not only target SIRT1 but also integrate into broader metabolic and neuroprotective pathways, presenting a promising approach to ameliorating AD symptoms. By elucidating the intricate interactions between SIRT1-modifying compounds and their effects on AD pathology, this review aims to advance the understanding of potential therapeutic strategies that could delay or prevent the progression of AD.

Keywords: Alzheimer’s disease; Neuroprotection; Sirtuin 1 (SIRT1) modulators; Synthetic and natural compounds; Therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Abed S, Ebrahimi A, Fattahi F, Kouchakali G, Shekari-Khaniani M, Mansoori-Derakhshan S (2024) The role of non-coding RNAs in mitochondrial dysfunction of Alzheimer’s disease. J Mol Neurosci 74:100. https://doi.org/10.1007/s12031-024-02262-y - PubMed
    1. Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM, Batiha GE (2023) Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev 92:102119. https://doi.org/10.1016/j.arr.2023.102119
    1. Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharmacal Res 36:375–399
    1. Armstrong RA (2019) Risk factors for Alzheimer’s disease. Folia Neuropathol 57:87–105
    1. Bandyopadhyay S, Goldstein L, Lahiri D, Rogers J (2007) Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer’s disease. Curr Med Chem 14:2848–2864 - PubMed

MeSH terms

LinkOut - more resources